Hospital
BMC - Attala, LLC
BMC - Attala, LLC was paid $8.77M by Medicaid between Jan 2018 and Dec 2024, across 113 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoBMC - ATTALA, LLC
KOSCIUSKO, MS 39090
KOSCIUSKO, MS 39090
33aNPI1730566027assigned 05/06/2015
33bProvider typeCritical Access Hospital
28Total paid$8.77M
24GClaims251,792
24DCodes billed113
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Mississippi
Rank by total paid#6 of 32
Median peer was paid$3.94M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,779 | $1.27M | |
| 2019 | 34,594 | $1.32M | |
| 2020 | 27,152 | $1.03M | |
| 2021 | 32,464 | $1.17M | |
| 2022 | 51,773 | $1.33M | |
| 2023 | 44,002 | $1.53M | |
| 2024incomplete | 26,028 | $1.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 15,884 | 12,693 | $1.98M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 8,698 | 6,900 | $1.35M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.6% | 4,700 | 3,755 | $846K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.4% | 7,399 | 6,106 | $564K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.0% | 4,733 | 3,672 | $350K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.3% | 8,032 | 5,849 | $287K |
| 71045 | Radiologic examination, chest; single view | 3.2% | 8,257 | 6,208 | $281K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.0% | 6,574 | 5,301 | $262K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.9% | 7,986 | 6,143 | $254K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.5% | 20,790 | 8,177 | $222K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.3% | 1,581 | 1,256 | $200K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.3% | 2,577 | 1,664 | $198K |
101 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 2,418 | $193K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 2,601 | $176K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 8,208 | $144K |
| G0378 | Hospital observation service, per hour | 1.5% | 489 | $135K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 2,290 | $128K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.3% | 4,948 | $117K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.2% | 7,500 | $105K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 3,017 | $102K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,532 | $81K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,541 | $76K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 424 | $73K |
| 83880 | <1% | 3,488 | $71K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 341 | $64K |
| 80053 | Comprehensive metabolic panel | <1% | 9,786 | $61K |
| 84484 | <1% | 7,286 | $48K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,841 | $47K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,902 | $38K |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,456 | $29K |
| A9270 | Non-covered item or service | <1% | 2,770 | $26K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 132 | $17K |
| 81001 | <1% | 8,675 | $17K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,565 | $17K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 98 | $17K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 208 | $14K |
| 81025 | <1% | 2,407 | $14K | |
| 87807 | <1% | 1,399 | $14K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 395 | $13K |
| 83735 | <1% | 2,668 | $10K | |
| 74018 | <1% | 211 | $9K | |
| 82553 | <1% | 1,059 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,686 | $8K |
| 83690 | <1% | 1,949 | $8K | |
| 82550 | <1% | 1,422 | $7K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 144 | $7K |
| 73560 | <1% | 155 | $7K | |
| 83605 | <1% | 1,195 | $6K | |
| 36600 | <1% | 279 | $6K | |
| 85610 | <1% | 2,162 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,611 | $5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 87 | $4K |
| 82803 | <1% | 287 | $4K | |
| 87040 | <1% | 689 | $4K | |
| 80305 | <1% | 469 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,437 | $3K |
| 87634 | <1% | 60 | $3K | |
| 73610 | <1% | 76 | $3K | |
| 87400 | <1% | 256 | $2K | |
| 73030 | <1% | 56 | $2K | |
| 80061 | Lipid panel | <1% | 207 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 31 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 340 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,541 | $2K |
| 87430 | <1% | 174 | $2K | |
| 85379 | <1% | 334 | $2K | |
| 82150 | <1% | 527 | $2K | |
| 85027 | <1% | 429 | $1K | |
| 73630 | <1% | 28 | $1K | |
| 87186 | <1% | 336 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 23 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 55 | $1K |
| 86900 | <1% | 19 | $876.74 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13 | $782.21 |
| 51702 | <1% | 16 | $776.70 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 21 | $693.40 |
| 87581 | <1% | 16 | $564.52 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,821 | $520.42 |
| 96376 | <1% | 151 | $505.08 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 349 | $477.80 |
| 0001A | <1% | 34 | $434.93 | |
| 96367 | <1% | 12 | $433.04 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,494 | $397.17 |
| 85730 | <1% | 168 | $352.04 | |
| 0002A | <1% | 15 | $333.03 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 47 | $332.68 |
| 86901 | <1% | 19 | $265.02 | |
| 86756 | <1% | 25 | $263.27 | |
| J2704 | Injection, propofol, 10 mg | <1% | 423 | $224.39 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 146 | $206.80 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 18 | $195.30 |
| 84703 | <1% | 25 | $174.21 | |
| 85007 | <1% | 52 | $136.57 | |
| 82009 | <1% | 18 | $70.28 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 41 | $57.28 |
| 80047 | <1% | 17 | $52.71 | |
| 86140 | <1% | 13 | $46.69 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 656 | $43.79 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 92 | $39.69 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,466 | $29.48 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 186 | $18.81 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 114 | $10.39 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 28 | $10.22 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 78 | $9.26 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 13 | $2.73 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 13 | $2.71 |
| 84145 | <1% | 39 | $1.98 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 61 | $0.16 |
| 94664 | 0% | 46 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 37 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 23 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 29 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUCKETT, GREGORY (SR VP/ CLO)
Parent organizationBAPTIST MEMORIAL HEALTH CARE CORP.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.